{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:16:01Z","timestamp":1779340561797,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jpba.2024.116227","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:19:44Z","timestamp":1715941184000},"page":"116227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Rapid identity testing of antibody-based hot targeted radionuclide therapies by bio-layer interferometry"],"prefix":"10.1016","volume":"246","author":[{"given":"Laurent","family":"Durous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol\u00e8ne","family":"G\u00e9raudie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Hunnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic G.","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Traenkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian Marius","family":"Gl\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116227_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1071086","article-title":"Targeted thorium-227 conjugates as treatment options in oncology","volume":"9","author":"Karlsson","year":"2023","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.jpba.2024.116227_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/CCO.0000000000000762","article-title":"Targeted radionuclide therapy: an emerging field in solid tumours","volume":"33","author":"Artigas","year":"2021","journal-title":"Curr. Opin. Oncol."},{"issue":"9","key":"10.1016\/j.jpba.2024.116227_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jpba.2024.116227_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-021-00123-2","article-title":"Guideline on current good radiopharmacy practice (CGRPP) for the small-scale preparation of radiopharmaceuticals","volume":"6","author":"Gillings","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"1","key":"10.1016\/j.jpba.2024.116227_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-019-0086-z","article-title":"EANM guideline on the validation of analytical methods for radiopharmaceuticals","volume":"5","author":"Gillings","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.jpba.2024.116227_bib6","unstructured":"EMA. I.C.H. Q2(R2): Validation of analytical procedures \u2013 Step 2b. European Medicines Agency. 2022. https:\/\/www.ema.europa.eu\/en\/ich-q2r2-validation-analytical-procedures-scientific-guideline."},{"issue":"4","key":"10.1016\/j.jpba.2024.116227_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/bios7040049","article-title":"Strategies using bio-layer interferometry biosensor technology for vaccine research and development","volume":"7","author":"Petersen","year":"2017","journal-title":"Biosensors"},{"key":"10.1016\/j.jpba.2024.116227_bib8","article-title":"State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization volume 2. Biopharmaceutical characterization: the NISTmAb case study","author":"Schiel","year":"2015","journal-title":"ACS\u00a0Symp.\u00a0Ser."},{"issue":"5","key":"10.1016\/j.jpba.2024.116227_bib9","first-page":"853","article-title":"Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus","volume":"409","author":"McLellan","year":"2011"},{"issue":"13","key":"10.1016\/j.jpba.2024.116227_bib10","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.3390\/cancers15133419","article-title":"Efficacy of a HER2-targeted thorium-227 conjugate in a HER2-positive breast cancer bone metastasis model","volume":"15","author":"Karlsson","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jpba.2024.116227_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ab.2016.06.024","article-title":"Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics","volume":"508","author":"Yang","year":"2016","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2024.116227_bib12","unstructured":"EMA. ICH M10 on bioanalytical method validation \u2013 Step 5. European Medicines Agency. 2022. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline."},{"key":"10.1016\/j.jpba.2024.116227_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejpb.2017.01.024","article-title":"How sugars protect proteins in the solid state and during drying (Review): mechanisms of stabilization in relation to stress conditions","volume":"114","author":"Mensink","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2024.116227_bib14","series-title":"General Chapter, \u30081058\u3009 Analytical Instrument Qualification","article-title":"USP-NF","author":"United States Pharmacopeia","year":"2023"},{"key":"10.1016\/j.jpba.2024.116227_bib15","unstructured":"Knowling, S. Harmonizing Regulatory Guidelines for Assay Validation: A Focus on Kinetics-Based Assays Using Octet\u00ae BLI Systems. Application note. https:\/\/www.sartorius.com\/resource\/blob\/1511214\/e66a5aa4a3 e2d38e0b96224ce3e55d5d\/assay-validation-guidelines-bli-application-note-en-sartoriu-1--data.pdf (accessed 2024-02-14)."},{"issue":"3","key":"10.1016\/j.jpba.2024.116227_bib16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpba.2010.09.008","article-title":"Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA","volume":"54","author":"McGivney","year":"2011","journal-title":"J.\u00a0Pharm. Biomed. Anal."},{"issue":"8","key":"10.1016\/j.jpba.2024.116227_bib17","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00216-018-0848-6","article-title":"Development of an LC-MS\/MS peptide mapping protocol for the NISTmAb","volume":"410","author":"Mouchahoir","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"issue":"5","key":"10.1016\/j.jpba.2024.116227_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1089\/hyb.1991.10.641","article-title":"An ELISA-method using magnetic beads as solid phase for rapid quantitation of mouse and human immunoglobulins","volume":"10","author":"R\u00f8nning","year":"1991","journal-title":"Hybridoma"},{"key":"10.1016\/j.jpba.2024.116227_bib19","unstructured":"EudraLex. Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Annex 11: Computerized systems. 2011. https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/annex11_01-2011_en_0.pdf."},{"key":"10.1016\/j.jpba.2024.116227_bib20","unstructured":"FDA. Part 11 Electronic Records Electronic Signatures Scope and Application. U.S. 2003. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/part-11-electronic-records-electronic-signatures-scope-and-application."},{"key":"10.1016\/j.jpba.2024.116227_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115580","article-title":"A comprehensive strategy for the identification of biologics by liquid-chromatography\u2013mass spectrometry for release testing in a regulated environment","volume":"234","author":"Morales","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116227_bib22","unstructured":"FDA. Guidance for Industry PAT -A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. 2004. https:\/\/www.fda.gov\/media\/71012\/download.."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852400267X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852400267X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:55:29Z","timestamp":1740797729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852400267X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":22,"alternative-id":["S073170852400267X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116227","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid identity testing of antibody-based hot targeted radionuclide therapies by bio-layer interferometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116227"}}